SE9701963D0 - Novel transcription factor - Google Patents

Novel transcription factor

Info

Publication number
SE9701963D0
SE9701963D0 SE9701963A SE9701963A SE9701963D0 SE 9701963 D0 SE9701963 D0 SE 9701963D0 SE 9701963 A SE9701963 A SE 9701963A SE 9701963 A SE9701963 A SE 9701963A SE 9701963 D0 SE9701963 D0 SE 9701963D0
Authority
SE
Sweden
Prior art keywords
freac
transcription factor
relates
novel transcription
adipose tissue
Prior art date
Application number
SE9701963A
Other languages
English (en)
Inventor
Sven Enerbaeck
Peter Carlsson
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Priority to SE9701963A priority Critical patent/SE9701963D0/sv
Publication of SE9701963D0 publication Critical patent/SE9701963D0/sv
Priority to JP50058699A priority patent/JP2002503102A/ja
Priority to DE69825594T priority patent/DE69825594T2/de
Priority to CA002291484A priority patent/CA2291484A1/en
Priority to AT98924724T priority patent/ATE273321T1/de
Priority to EP98924724A priority patent/EP1003776B1/en
Priority to NZ501804A priority patent/NZ501804A/en
Priority to PCT/SE1998/000989 priority patent/WO1998054216A1/en
Priority to AU76826/98A priority patent/AU742500B2/en
Priority to NO19995786A priority patent/NO324817B1/no
Priority to US09/587,945 priority patent/US6709860B1/en
Priority to US10/806,782 priority patent/US20040166061A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE9701963A 1997-05-26 1997-05-26 Novel transcription factor SE9701963D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE9701963A SE9701963D0 (sv) 1997-05-26 1997-05-26 Novel transcription factor
AU76826/98A AU742500B2 (en) 1997-05-26 1998-05-26 Gene and amino acid sequences for novel transcription factor
AT98924724T ATE273321T1 (de) 1997-05-26 1998-05-26 Screening-methode unter verwendung des freac-11 transkriptionsfaktors
DE69825594T DE69825594T2 (de) 1997-05-26 1998-05-26 Screening-Methode unter Verwendung des FREAC-11 Transkriptionsfaktors
CA002291484A CA2291484A1 (en) 1997-05-26 1998-05-26 Gene and amino acid sequences for novel transcription factor
JP50058699A JP2002503102A (ja) 1997-05-26 1998-05-26 新規な転写因子に関する遺伝子およびアミノ酸配列
EP98924724A EP1003776B1 (en) 1997-05-26 1998-05-26 Screening method using FREAC-11 transcription factor
NZ501804A NZ501804A (en) 1997-05-26 1998-05-26 FREAC-11 gene (encoding 110 amino acid DNA binding domain of FREAC 11 binds to cis elements) and transcription factors as regulatory elements to treat obesity related diseases
PCT/SE1998/000989 WO1998054216A1 (en) 1997-05-26 1998-05-26 Gene and amino acid sequences for novel transcription factor
NO19995786A NO324817B1 (no) 1997-05-26 1999-11-25 Fremgangsmate for screening av stoffer som pavirker aktiviteten til FREAC 11
US09/587,945 US6709860B1 (en) 1997-05-26 2000-06-06 Animal model
US10/806,782 US20040166061A1 (en) 1997-05-26 2004-03-23 Animal model

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9701963A SE9701963D0 (sv) 1997-05-26 1997-05-26 Novel transcription factor

Publications (1)

Publication Number Publication Date
SE9701963D0 true SE9701963D0 (sv) 1997-05-26

Family

ID=20407085

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9701963A SE9701963D0 (sv) 1997-05-26 1997-05-26 Novel transcription factor

Country Status (10)

Country Link
EP (1) EP1003776B1 (sv)
JP (1) JP2002503102A (sv)
AT (1) ATE273321T1 (sv)
AU (1) AU742500B2 (sv)
CA (1) CA2291484A1 (sv)
DE (1) DE69825594T2 (sv)
NO (1) NO324817B1 (sv)
NZ (1) NZ501804A (sv)
SE (1) SE9701963D0 (sv)
WO (1) WO1998054216A1 (sv)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150951A0 (en) * 2000-02-18 2003-02-12 Biovitrum Ab Transgenic animal model for obesity expressing foxc2
CA2421620A1 (en) * 2000-09-26 2002-04-04 Biovitrum Ab Promoter sequences
JP2005538930A (ja) * 2002-01-29 2005-12-22 リーンジーン・アクチボラゲット ヒトｆｏｘｃ２タンパク質およびｆｏｘｃ−２相互作用タンパク質の複合体
US7955795B2 (en) 2003-06-06 2011-06-07 Qiagen Gmbh Method of whole genome amplification with reduced artifact production
WO2005099363A2 (en) 2004-03-26 2005-10-27 Whitehead Institute For Biomedical Research Methods of diagnosing, preventing and treating cancer metastasis
EP1762627A1 (de) 2005-09-09 2007-03-14 Qiagen GmbH Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563036A (en) * 1994-04-29 1996-10-08 Tularik, Inc. Transcription factor-DNA binding assay

Also Published As

Publication number Publication date
DE69825594D1 (de) 2004-09-16
NO995786L (no) 2000-01-25
NO324817B1 (no) 2007-12-10
NO995786D0 (no) 1999-11-25
AU742500B2 (en) 2002-01-03
NZ501804A (en) 2002-06-28
WO1998054216A1 (en) 1998-12-03
ATE273321T1 (de) 2004-08-15
JP2002503102A (ja) 2002-01-29
DE69825594T2 (de) 2005-09-15
EP1003776B1 (en) 2004-08-11
CA2291484A1 (en) 1998-12-03
EP1003776A1 (en) 2000-05-31
AU7682698A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
DE69635609D1 (de) Nukleinsäure enthaltende zusammensetzung, herstellung und verwendung
BR0207325A (pt) Métodos terapêuticos para doenças associadas com expressão diminuìda de gene de aop-1 ou aop-1
BR9808998A (pt) Imidazóis substituìdos úteis no tratamento de doenças inflamatórias
WO1997012986A3 (en) Non-group c adenoviral vectors
BR9711046A (pt) Ligando relacionado a fator de necrose de tumor.
SE9701963D0 (sv) Novel transcription factor
BR9811865A (pt) Isolamento de um novo gene de fator de senescência, p23
HUP0001693A2 (hu) Alfa-hidroxisavak és/vagy aromás o-hidroxisavak alacsony molekulatömegű oligomer észtereinek alkalmazása kozmetikai készítményekben
EA200100583A1 (ru) Композиции, содержащие лактадгерин или его варианты, и способы их использования
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
FR2744455B1 (fr) Nouvelles sequences d'acides nucleiques de la famille des facteurs suppresseurs de tumeurs, produits d'expression correspondants et leurs applications
AU4263696A (en) Peptides capable of binding to the gap protein sh3 domain, nucleotide sequences coding therefor, and preparation and use thereof
EP0773290A3 (en) Novel LDL receptor analog protein and the gene coding therefor
BR9708005A (pt) C3 convertase resistente à regulação para baixo
ATE371737T1 (de) Proteaseresistente flint-analoge
BR9811954A (pt) ácidos 3-aril-succinamido-hidroxâmicos, processos para sua produção e preparações farmacêuticas contendo estas substâncias
BR9808625A (pt) O uso de proteìnas extraìveis de órgãos de animal para a preparação de medicamentos para o tratamento de condições patológicas caracterizadas por hiperprodução de fator de necrose de tumor (tnf)
ATE253883T1 (de) Dentaladhäsive
BG101846A (en) HUMAN DNase I VARIANTS
BR9908518A (pt) Utilização do fator de crescimento de monócitos cd137 ou de um análogo funcional do mesmo, processos in vitro para promover a proliferação de monócitos periféricos, para o tratamento regenerativo de pacientes de quimioterapia ou de terapia com radiação, e para promover a defesa imunológica não-especìfica endógena, utilização de uma sequencia de nucleotìdeos que codifica para cd137 ou um análogo funcional do mesmo, composição de terapia de genes, e, processo de terapia de genes para o tratamento de um dos distúrbios
TR200003352T2 (tr) Yeni pentaerythrit türevleri, bunların imalatı ve kullanımları ile bunların sentezi için ara maddeler
HUP9901346A2 (hu) Deltap62 polipeptid és variánsai, ezeket kódoló nukleinsav-szekvenciák és felhasználásuk
NO20023914D0 (no) Preparater for anvendelse ved regulering av Parkin- genaktiviteten
BG101847A (en) Human dnase i variants
YU5296A (sh) Proteini protiv gojaznosti